SEC Comment Letter 0000000000-22-012918 to Enfusion, Inc. (ENFN) (CIK 0001868912)
Enfusion, Inc. (ENFN) (CIK 0001868912)
Date: Nov. 30, 2022 · CIK: 0001868912 · Accession: 0000000000-22-012918
AI Filing Summary & Sentiment
File numbers found in text: 333-268477
Letter
United States securities and exchange commission logo November 30, 2022 Oleg Movchan Interim Chief Executive Officer Enfusion, Inc. 125 South Clark Street, Suite 750 Chicago, IL 60603 Re:Enfusion, Inc. Registration Statement on Form S-3 Filed November 18, 2022 File No. 333-268477 Dear Oleg Movchan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Aliya Ishmukhamedova, Law Clerk, at 202-551-2336 or Jan Woo, Legal Branch Chief, at 202- 551-3453 with any questions. Sincerely, Division of Corporation Finance Office of Technology cc: Gregg L. Katz
Show Raw Text
United States securities and exchange commission logo
November 30, 2022
Oleg Movchan
Interim Chief Executive Officer
Enfusion, Inc.
125 South Clark Street, Suite 750
Chicago, IL 60603
Re:Enfusion, Inc.
Registration Statement on Form S-3
Filed November 18, 2022
File No. 333-268477
Dear Oleg Movchan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Aliya Ishmukhamedova, Law Clerk, at 202-551-2336 or Jan Woo, Legal
Branch Chief, at 202- 551-3453 with any questions.
Sincerely,
Division of Corporation Finance
Office of Technology
cc: Gregg L. Katz